ABSTRACT: Introduction: Agrin is essential for the formation and maintenance of neuromuscular junctions (NMJs). NT-1654 is a C-terminal fragment of mouse neural agrin. In this study, we determined the effects of NT-1654 on the severity of experimental autoimmune myasthenia gravis (EAMG). Methods: EAMG was induced in female Lewis rats by immunization with the Torpedo acetylcholine receptor (tAChR) and complete Freund's adjuvant (CFA). NT-1654 was dissolved in phosphatebuffered saline (PBS) and injected daily subcutaneously into tAChR immunized rats during the first 10 days after immunization, and then every other day for the following 20 days. Results: We showed that NT-1654 attenuated clinical severity, effectively promoted the clustering of AChRs at NMJs, and alleviated the impairment of NMJ transmission and the reduction of muscle-specific kinase (MuSK) in EAMG rats. Discussion: We demonstrated that NT-1654 attenuated clinical severity, effectively promoted the clustering of AChRs at NMJs, and alleviated the impairment of NMJ transmission and the reduction of muscle-specific kinase (MuSK) in EAMG rats.
nance of neuromuscular junctions (NMJs). NT-1654 is a C-terminal fragment of mouse neural agrin. NT-1654 and agrin share the same mechanism of action by binding to the low-density lipoprotein receptorrelated protein 4 (LRP4) to activate muscle-specific kinase (MuSK)/docking protein 7 (DOK7) signaling and subsequently inducing rapsyn dependent acetylcholine receptor (AChR) assembly and aggregation at the NMJ. [1] [2] [3] [4] [5] [6] Unlike endogenous neural agrin, NT-1654 is engineered to be highly soluble and resistant to cleavage by neurotrypsin, which is a protease that counteracts the activity of agrin in the synaptic cleft. 7, 8 NT-1654 has been shown to induce AChR clustering and to be effective in attenuating the sarcopenia-like phenotype in neurotrypsinoverexpressing (SARCO) mice. 2 Myasthenia gravis (MG) is an immune-mediated neuromuscular disorder in which antibodies to the NMJ acetylcholine receptors or other antigens of postsynaptic skeletal muscle impair NMJ transmission and result in weakness of voluntary skeletal muscles. 4, [9] [10] [11] These pathogenic antibodies have several effects that cause clinical weakness; the most important of these is activation of the complement system and subsequent remodeling of the postsynaptic membrane of the NMJ. 12 This remodeling results in decreased numbers of AChR, loss of the junctional folds that hold the receptors, reduced clustering of the receptors and, ultimately, long-term changes that may contribute to disability in affected patients. Untreated, the disease has high morbidity related to the frequent bulbar and respiratory weakness. 13 While current treatment with corticosteroids or immunomodulating agents can be effective at reducing this morbidity and alleviating symptoms, it also carries significant risks and adverse effects. There is an unmet need in this respect for agents that can help treat MG while reducing the doses of these immunomodulatory agents. Because standard immunotherapy involves reducing the pathogenic effects of disease causing antibodies, 14 strategies that enhance repair of these changes are attractive as potential adjunctive therapies to immunomodulation.
Experimental autoimmune MG (EAMG) reliably recapitulates many of the features seen in human disease. It is routinely induced in susceptible mouse or rat strains by immunization with Torpedo AChR (tAChR) and CFA. 15, 16 After immunization, EAMG animals display reduced AChR clustering and impaired neurotransmission at their NMJs, which closely mimics the immunopathological and electrophysiological features of human disease. 17, 18 In this study, we evaluated the impact of NT-1654 on the severity of EAMG. In particular, we studied its ability to modify the clinical course of EAMG and its impact on the immunopathological and electrophysiological features of NMJs in EAMG.
MATERIALS AND METHODS
Animals. Female Lewis rats, 8-10 weeks of age, were purchased from Charles River Laboratories International, Inc. (Wilmington, MA). A total of 48 rats (n 5 12 per group) were assigned to 4 groups: EAMG, EAMG treated with NT-1654 (2 mg/kg), EAMG treated with NT-1654 (6 mg/kg), and healthy na€ ıve control. All rats were housed and handled in specific pathogen-free conditions according to approved protocol of the Institutional Animal Care and Use Committee at Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Antigen Preparation, Immunization, and Clinical Evaluation of EAMG. The tAChR was purified from the electric organs of Torpedo californica (Pacific Bio-Marine Laboratories, Inc., Venice, CA) by affinity chromatography on an a-cobratoxinagarose resin (Sigma-Aldrich Co., LLC, St. Louis, MO) as previously described. [19] [20] [21] A total of 36 rats were subcutaneously injected in the hind foot pads and at the base of the tail on day 0 with 50 mg of purified tAChR emulsified in CFA for a total volume of 200 ll. 22 For clinical examination, body weight and assigned clinical scores were evaluated blindly at least by two investigators from day 1 to day 49 after immunization. Disease severity of muscle weakness was assessed as has been previously described and scored as follows: (0) healthy normal rats with no signs of EAMG; (1) mildly decreased activity and weak grip with fatigability; (2) weakness, hunched posture at rest, decreased body weight, and tremor; (3) severe generalized weakness, marked decrease in body weight, moribund; (4) death. 15, 23, 24 All rats were killed at day 49 after initial tAChR immunization.
NT-1654 Administration. NT-1654 was provided gratis by Neurotune (Neurotune AG, Schlieren-Zurich, Switzerland) and was dissolved in PBS at a concentration of 2 mg/ ml. From day 1 to day 30 after tAChR immunization, EAMG rats received subcutaneous injections of either vehicle PBS only, vehicle containing 2 mg/kg NT-1654, or vehicle containing 6 mg/kg NT-1654. Injections were administrated once a day from day 1 to day 10 and then once every other day from day 11 to day 30. Na€ ıve control rats were subjected to subcutaneous injections of vehicle PBS using the same injection schedule.
Electromyography (EMG).
Repetitive nerve stimulation was performed to record compound muscle action potentials (CMAPs) at day 49 after immunization. Rats were anesthetized with a cocktail of ketamine and xylazine (60 mg/kg and 10 mg/kg body weight, respectively) and were maintained at 378C on a heating pad throughout the process. The stimulating electrode containing an anode and a cathode was placed near sciatic nerve in the thigh of the left leg. The recording needle electrode was inserted into the middle of the tibialis anterior muscle of the left leg, and the reference needle electrode was inserted near the calcaneal tendon. The reference and recording electrodes were connected to a Sierra Wave amplifier (Cadwell, Kennewick, WA). Repetitive nerve stimulation was performed on the sciatic nerve with 10 trains of 10 stimuli at several frequencies (1, 10, 20 , and 40 HZ) according to other previous studies. 10, 25 Thereafter, CMAPs were recorded and peak-to-peak data were measured with Sierra Wave 11.0 (Cadwell, Kennewick, WA).
Immunostaining. The animals were killed at day 49 after immunization. The tibialis anterior muscles were obtained and were fixed overnight in 4% paraformaldehyde (PFA) before paraffin embedding. For whole-mount muscle tissue staining and analysis, the tissue blocks were cut into 6-lm cross-sections and every twentieth section was stained. For immunofluorescence, muscle sections (three sections per tissue block) were incubated in blocking buffer consisting of 5% goat serum with 1% bovine serum albumin in 0.1% Triton X-100 in PBS for 2 h. Subsequently, the muscle sections were incubated overnight at 48C with a-bungarotoxin conjugated with Alexa FluorV R 594 (1:2,000; Cat. No. B13423, Thermo Fisher Scientific, Inc., Anthem, AZ) and antibodies against neurofilament heavy chain (NF-H) (1:100; Cat. No. sc-20112, Santa Cruz Biotechnology, Paso Robles, CA), synaptic vesicle glycoprotein 2A (SV2A) (1:100; Cat. No. sc-376234, Santa Cruz Biotechnology, Paso Robles, CA). After the tissue sections were washed three times in PBS, they were incubated with Alexa Fluor 488-conjugated secondary antibody (1:1,000; Thermo Fisher Scientific, Inc., Anthem, AZ) for 2 h at room temperature.
Finally, the slices were incubated with fluoroshield mounting medium with DAPI (Abcam, Inc, Cambridge, MA) for 5 min before images (four random fields per section) were taken with a fluorescence microscopy (model BX61, Olympus, Center Valley, PA). For immunohistochemical analysis, tissue sections (10 sections per tissue block) were stained with hematoxylin-eosin, and microscopic images (four random fields per section) were obtained (model BX61, Olympus, Center Valley, PA). All image data were analyzed and quantified by using ImageJ open-source software (U.S. National Institutes of Health, Washington, DC).
Western Blot. The tibialis anterior muscles were obtained at day 49 after immunization and sacrifice, and were lysed in RIPA buffer (Cell Signaling Technology, Inc., Danvers, MA) supplemented with a protease inhibitor cocktail (SigmaAldrich Co., LLC, St. Louis, MO) for 1 h at 48C. Then protein concentration was measured and tissue lysates were subjected to Western blotting. Whole tissue lysates containing 40 lg of protein were resolved by 10% SDS-PAGE and transferred to polyvinyl difluoride (PVDF) membranes using a transfer apparatus (Bio-Rad Laboratories, Inc., Philadelphia, PA) according to the manufacturer's protocol. The PVDF membranes were incubated with 5% nonfat milk in Tris-buffered saline and Tween 20 buffer containing primary antibodies against MuSK (1:100; Cat. No. sc-6009, Santa Cruz Biotechnology, Paso Robles, CA) or a-tubulin (1:1,000; Cat. No. sc-23948, Santa Cruz Biotechnology, Paso Robles, CA) at 48C overnight. After the PVDF membranes were washed twice with TBST, they were incubated with horseradish peroxidase-conjugated rat antimouse IgG (1: 2,000; Thermo Fisher Scientific, Inc., Anthem, AZ) or rabbit anti-goat IgG (1: 1,000; Invitrogen, Carlsbad, CA) for 1 h at room temperature. Immunoreactive bands were detected using enhanced chemiluminescence (Thermo Fisher Scientific, Inc., Rockford, IL) and captured with an Odyssey Fc Imaging System (LI-COR, Inc., Lincoln, NE). Western blot data were analyzed with ImageJ software.
Statistics. Data were normally distributed and analyzed using a two-tailed unpaired Student's t-test for two groups or analysis of variance for multiple comparisons, followed by Tukey post hoc test using GraphPad Prism 7.01 (GraphPad Software. Inc). Data were expressed as mean 6 SEM unless otherwise indicated. A P value less than 0.05 was considered significant and expressed in figures as P < 0.05 or P < 0.01.
RESULTS
NT-1654 Administration Ameliorates EAMG. After tAChR immunization, Lewis rats receiving vehicle PBS served as disease (EAMG) controls and developed typical two-phase EAMG, with an early phase of muscular weakness followed by a late phase of progressive muscular weakness during the 7-week observation period (Fig. 1A) . EAMG rats treated with NT-1654 were found to have less severe clinical scores in both the early and late phases of disease. At day 49 after immunization, 2 mg/kg NT-1654 and 6 mg/kg NT-1654 treated EAMG rats had a reduction in clinical scores of 42.86% and 71.43%, respectively, when compared with disease control rats, suggesting that the therapeutic effect of NT-1654 is dose dependent (Fig. 1A) . The 2 mg/kg NT-1654 and 6 mg/kg NT-1654 treated EAMG rats also had more weight gain by 4.12% and 5.70%, respectively, when compared with disease control rats at day 49 (Fig. 1B) . In addition, no difference was seen in percent body weight gain among the healthy and treated rats. Overall, these results suggest that early treatment with NT-1654 can attenuate the clinical severity of EAMG.
NT-1654 Improves Electrophysiologic Measures of Neuromuscular Transmission. In healthy control rats, there was little or no decrement after 10 consecutive nerve stimuli at 1 HZ, 10 HZ, 20 HZ, and 40 HZ. In contrast to healthy controls, disease control rats stimulated at 40 HZ had a mean decrement response of 11.1% by the fourth stimulus and 19.9% by the tenth stimulus ( Fig. 2A,B) . In contrast, EAMG rats treated with 2 mg/kg and 6 mg/kg of NT-1654 and stimulated at 40 HZ had a mean decremental response of 5.1% (P 5 0.073) and 5.3% (P 5 0.089) by the fourth stimulus and of 12.8 % and 10.4% by the tenth stimulus, respectively, compared with healthy control's (Fig. 2B ). This effect appeared to be greater in the 6 mg/kg group than in the 2 mg/kg group (Fig. 2C ), in keeping with the dose-dependent response observed in our other measures of disease severity. Overall, these data suggest that NT-1654 can attenuate neuromuscular transmission dysfunction in treated EAMG rats compared with disease control rats.
Effects of NT-1654 Treatment on Neuromuscular
Junction Pathology. Quantification of the immunofluorescence intensity of AChR showed a reduction of 42.1% in disease control rats relative to healthy controls (Fig. 3A,B) . In addition to the loss of AChR clusters, the intensity of AChR and nerve terminals (a-bungarotoxin and NF-H/SV2A double positive) were reduced by 43.8% in disease control rats compared with healthy controls (Fig. 3A,C) . When we compared EAMG rats treated with 2 mg/kg and 6 mg/kg of NT-1654 with disease controls, there was increased immunofluorescence intensity of AChR of 21.3% and 27.1%, respectively (Fig. 3 A,B) . Moreover, the overlap percentage of AChR to nerve terminals was also significantly increased by 17.4% and 23.9% in EAMG rats receiving 2 mg/kg and 6 mg/kg of NT-1654, respectively (Fig. 3D ). In keeping with the ameliorated clinical disease severity and neuromuscular transmission dysfunction seen after NT-1654 treatment, these data showed that NT-1654 also attenuates the loss of AChR in NMJ of EAMG rats.
NT-1654 Treatment Ameliorates Muscular Atrophy in EAMG.
Tissue cross-sections of the tibialis anterior muscle were obtained at day 49 after EAMG induction. Muscle fiber atrophy was visualized in EAMG muscle cross-sections stained with hematoxylineosin (Fig. 4A) . Quantitative morphometric evaluation of the fiber size distribution demonstrated the obvious shift toward smaller fibers in disease (EAMG) control rats than in healthy control muscles (Fig. 4B) . Treatment with NT-1654 significantly reversed the size distribution of muscle fibers (Fig. 4B ). This result suggests that NT-1654 treatment can at least partially prevent muscular atrophy in EAMG.
NT-1654 Treatment Enhances Resilience of the MuSK
Protein in EAMG. The reduction of MuSK expression was evident in disease (EAMG) control rats compared with healthy controls (Fig. 5) , indicating the loss of MuSK in conjunction with abnormal NMJ structures in EAMG. In EAMG rats treated with NT-1654, protein level of MuSK was significantly higher than in disease control rats when analyzed by Western blotting analysis (Fig. 5A,B) . The protein level of MuSK was not significantly different between groups of EAMG rats receiving 2 mg/kg versus 6 mg/kg NT-1654. Different from the finding in MuSK protein levels, we found that NT-1654 treatment did not significantly alter the mRNA level of MuSK in EAMG rats, suggesting that mechanisms other than mRNA upregulation might be involved in the augment of MuSK protein levels after NT-1654 treatment (data not shown). Together, these findings suggest that NT-1654 attenuate the reduction of MuSK protein in injured NMJ of EAMG rats.
DISCUSSION
The mainstay of treatment for MG has been a combination of acetylcholinesterase inhibitors that improve availability of acetylcholine at the NMJ and immunomodulating agents that blunt the immune attack on AChRs at the NMJ. Although effective, these treatments are associated with substantial long and short term adverse effects. [26] [27] [28] Additionally, none of these treatments directly improve or reverse the structural changes that occur at the postsynaptic membrane secondary to the immune attack on the AChRs. In this study, we demonstrate that the recombinant agrin fragment NT-1654 improves AChR clustering and NMJ transmission in EMAG rats, supporting further therapeutic development of this compound.
Our pathologic data supported the effect of NT-1654 on neuromuscular junction repair. The number of AChRs identified by immunofluorescence was increased by treatment with NT-1654 and, importantly, these were localized at the NMJ in the muscle. Improvement in fiber size distribution after NT-1654 treatment was also observed. Muscle atrophy has been reported to be related to functional denervation of muscle fibers but also likely to weakness-induced disuse. 29 Thus, this is likely to be a secondary effect of decreased weakness and increased AChR numbers at the NMJ rather than a direct effect on muscle fibers.
The effect of agrin on AChR stabilization is thought to be concentration dependent. [30] [31] [32] In keeping with that, we found that rats treated with the higher dose (6 mg/kg) of NT-1654 had greater AChR clustering and clinical response than rats treated with the lower dose (2 mg/kg). However, given the small cohort sizes, no definite conclusions can be drawn, and further investigation is necessary. Furthermore, it remains to be determined whether higher doses of NT-1654 may be more effective or whether concomitant treatment with immunomodulatory agents, which are commonly used in treatment of MG, may alter the dosing or have a synergistic effect.
Our data support further investigation of NT-1654 in EAMG and human MG. This study could not address some questions that would be relevant to human MG. In the current study, NT-1654 was administered immediately after EAMG induction and the clinical benefits were observed over the course of the disease, suggesting that the effect was long lasting. However, in humans, MG is treated only after symptoms have developed and antibody generation is well underway. It is not clear whether treatment with NT-1654 would be beneficial if initiated during the chronic phase of EAMG after the immune attack on the NMJ has had time to cause structural end-plate changes. This should be a focus of further studies in the development of NT-1654.
Another observation was that, despite administration of the last dose of NT-1654 on day 30, the clinical assessments, muscle pathology and electrophysiological testing performed on day 49 showed beneficial effect, which suggests a relatively longlasting effect on the NMJ. Because agrin and its targets including MuSK and rapsyn play an essential role in inducing AChR clustering and maintaining the structure and function of NMJ, 6 ,33 one possibility is that treatment with NT-1654 helps to prevent the loss of proteins including MuSK of NMJs, allowing NMJ function to endure the immune attack and makes the NMJ less susceptible to the chronic phase of EAMG after the compound is no longer present. This could indicate that the effectiveness of the compound is due to its action during the acute phase of EAMG, and that it may not be useful in human MG. Thus, the long-lasting clinical improvement after completion of administration of NT-1654 suggests that NT-1654 should be evaluated by administration during later time points in the disease process and by use in other animal models of myasthenia gravis.
No adverse effects of NT-1654 were seen during the study. The nature of NT-1654's structure and mechanism raise certain potential safety concerns. The compound could induce antibody formation or an immune response that could either inhibit its activity or cause hypersensitivity reactions. Our data suggests that anti-agrin antibodies are not produced after treatment with NT-1654. Another study of NT-1654 immunogenicity in rats also did not demonstrate a significant immune response after 8 weeks of treatment (personal communication, S. Hettwer, PhD). An additional concern is the theoretical possibility of ectopic AChR formation which 
